This topic contains a solution. Click here to go to the answer

Author Question: Patients who are being treated for folate deficiency require monitoring of: 1. Complete blood ... (Read 31 times)

c0205847

  • Hero Member
  • *****
  • Posts: 531
Patients who are being treated for folate deficiency require monitoring of:
 
  1. Complete blood count every 4 weeks
  2. Hematocrit and hemoglobin at 1 week and then at 8 weeks
  3. Reticulocyte count at 1 week
  4. Folate levels every 4 weeks until hemoglobin stabilizes

Question 2

Monitoring for a patient taking iron to treat iron deficiency anemia is:
 
  1. Hemoglobin, hematocrit, and ferritin 4 weeks after treatment is started
  2. Complete blood count every 4 weeks throughout treatment
  3. Annual complete blood count
  4. Reticulocyte count in 4 weeks



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

ryhom

  • Sr. Member
  • ****
  • Posts: 366
Answer to Question 1

2

Answer to Question 2

1




c0205847

  • Member
  • Posts: 531
Reply 2 on: Jul 24, 2018
Great answer, keep it coming :)


AISCAMPING

  • Member
  • Posts: 347
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

Colchicine is a highly poisonous alkaloid originally extracted from a type of saffron plant that is used mainly to treat gout.

Did you know?

People often find it difficult to accept the idea that bacteria can be beneficial and improve health. Lactic acid bacteria are good, and when eaten, these bacteria improve health and increase longevity. These bacteria included in foods such as yogurt.

Did you know?

Fewer than 10% of babies are born on their exact due dates, 50% are born within 1 week of the due date, and 90% are born within 2 weeks of the date.

Did you know?

The newest statin drug, rosuvastatin, has been called a superstatin because it appears to reduce LDL cholesterol to a greater degree than the other approved statin drugs.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

For a complete list of videos, visit our video library